The amended dosing regimen was approved based on results from a post hoc analysis of the phase 2 MagnetisMM-3 trial.

Patients receiving subcutaneous daratumumab have less chair time and premedication than those receiving IV formulation, says ...

Sanofi reported $471 million in Sarclisa sales last year, a healthy 30% increase on the prior year, but it remains dwarfed by Darzalex (daratumumab), whose 2024 sales approached $12 billion, with ...